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Nanomedicine utilizes biocompatible nanomaterials for therapeutic as well as imaging purposes for the
treatment of various diseases including cancer, neurological disorders and wound infections. Graphene
and its modified nanostructures have attracted much attention in recent years in nanomedicine owing to
their scalable and cost effective preparation and physiochemical features (high specific surface area, ease
in conjugation to peptides/antibodies/proteins and biocompatibility). However, the limited fabrication,
functionalization, and in vivo functionalities available in literature indicate inconsistencies regarding the
factors affecting in vivo metabolisms, biodistribution as well as toxicity patterns of graphene. It appears
that redox signaling pathways, and their proper use to target specific diseases and to improve
biocompatibility and interplay between size and optical properties are key determinants to investigate
the metabolic fate of such materials. This featured letter provides key insights into the significance and
multifunctional roles of redox regulated species in graphene-based materials which can be used to
closely mimic therapeutic functions, navigating new paths to nanomedicine and synthetic biology.
Furthermore, this letter focuses on the missing functionalities and challenges in using graphene-based
materials as both nano-carriers and nano-drugs in various biomedical sectors which might be favor-
able for multiple payloads and drug targeting in upcoming years.
© 2018 The Author. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The use of graphene is becoming well established in the fields of
photonics and electronics, but it is only now, with the technologies
maturing, that it is branching out into new areas such as nano-
medicine and synthetic biology, and it promises to revolutionize
clinical settings across the board in areas including but not limited
to drug delivery systems for theranostics, high throughput bio-
sensors and bioassay, smart scaffolds for tissue regeneration, and
ultra-high sensitive biomarkers [1e3]. Graphene is known as a
relatively inexpensive archetypal monolayer framework of carbon
species, amongst carbon nanotubes and fullerenes andmany others
[4]. The unique and tunable features of graphene-based materials
(including pristine graphene, graphene oxide, reduced graphene
oxide, graphene quantum dots (GQDs), graphene nanoribbons,
graphene nanoplatelets, three dimensional graphene foam and
many others) promise many new approaches in medical in-
terventions, where its high surface area, exceptional electronic
features and high mechanical strength could be a boon for drug
delivery techniques [5] (See Fig. 1). Their lateral dimensions andInc. This is an open access articlethickness can be tuned between nano-to mili-meters and mono-to
few-layers, respectively; additionally, their two-dimensional na-
ture can be modified to zero, one, and three-dimensional assem-
blies [6e8]. Graphene-basedmaterials are perhaps the first systems
to take advantage of such a tunability approach among other
nanomaterials, improving the accumulation of drug vehicles and
contrast agents at specific target sites in different diseases [9].
Graphite is a layered structure; each layer packed in a hexagonal
lattice, while graphene is one atomic thin layer of graphite which is
formed of sp2 hybridised carbon atoms composed in a hexagonal/
honeycomb lattice [10,11]. In other words, graphite is composed of
many layers of graphene [12]. It is well known that single layer
graphene has not been achieved via exfoliation of graphite, which is
another drawback in commercial applications of graphene [13e15].
As theoretically graphene has superficial electrical and mechanical
properties which has not been obtained experimentally due to
insufficient oxidation and/or inadequate reaction conditions that
may importantly build-up for the isolation of single layer graphene
and in turn achieve exceptional characteristics of graphene inter-
calated compounds.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig.. 1A schematic illustration of the biological applications of graphene-based materials, the potential mechanism of toxicity and graphene-mediated reactive oxygen and nitrogen
species (RONS) generation. The lower panel represents the synthesis and structural models of graphene oxide and reduced graphene oxide. Chemical preparation of graphene is
generally carried out by oxidation and exfoliation of graphite flakes while reduced graphene oxide is prepared by reduction of graphene oxide using a variety of reducing agents
such as hydrazine, sulfur, nitrogen etc, which helps eliminate the oxygen containing functional groups existing on the surface of graphene. The upper right panel refers to the
biomedical application of graphene-based materials such as cancer, infectious, inflammatory, and cardiovascular and neurodegenerative diseases and the middle panel represents
the oxygen and nitrogen centred species such as hydroxyl radical (OH), hydrogen peroxide (H2O2),superoxide (O2), singlet oxygen ((1O2), ONOO (peroxynitrite), nitric oxide
(NO). The left panel shows the potential toxic pathways of graphene within a cell such as cell cycle arrest, apoptosis, damage to the cell membrane, mitochondrial and DNA damages.
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Biomedical applications of graphene are currently in their in-
fancy, and over the past decade, the use of graphene-based nano-
materials in cancer diagnosis and therapy alongwith their potential
toxic effects have become increasingly important [16]. The
continuous and widespread exposure of graphene-based materials
raises urgent occupational, environmental and health concerns to
living organisms. Although recent studies have demonstrated the
in vitro and in vivo applicability of graphene in nanomedicine, there
still exists a critical need to explore the potential health benefits
and risks of three-dimensional graphene foam and graphene
nanoribbons in living models [17]. We have recently undertaken
the first pilot toxicology study on 3D graphene foam, and have
demonstrated that graphene foam does not show any acute toxicity
in common carps (a standard test-bed for toxicology); histological
imaging revealed that graphene foam indeed remained within liver
and kidney macrophages for 7 days without severe inflammation
and damages to the tissues [8], providing evidence that these ma-
terials are both eco-friendly and highly biocompatible in a dose-
and time-dependent manner. Nanostructured graphene can enter
and be deposited at non-target cells intracellularly via their trans-
location across biological barriers. Consequently, graphene can
induce off-target adverse effects. Recent in vitro and in vivo studies
on the anticancer activities associated with toxicity of graphene
nanostructures in mammalian and non-mammalian cells, and non-
primate models have also demonstrated that graphene oxide, and
reduced graphene oxide can provoke toxic effects [18]. Most
importantly, surface functionalization of these materials may
considerably help reduce their apparent toxic interactions with
cellular and animal model's biochemistry. However, the dissemi-
nation of redox signaling (reactive oxygen and nitrogen species) is
considered to be of critical importance in the expansion of such
novel nanoformulations to improve the bioavailability and unat-
tainable functionality [19,20]. Selection of precursors, residual
solvents, and reaction conditions are critically important inevaluating the potential toxic effects of graphene-based materials
in disease diagnosis and treatment. PEGylation and other non-toxic
and -biodegradable functionalization routes have recently been
reported to reduce toxicities and side-effects in non-specific
shielding of graphene, which have been widely explored in
in vitro cell cultures [21,22]. Furthermore, tagging of such peptides
and antibodies to the graphene nanostructures may affect the
pharmacokinetics, targeting efficacy and safety of nanomedicines
[23]. In vivo toxicity findings for long-term acute and chronic cir-
culation, biodistribution, specific targeting within diseased cells
and clearance of nanomedicines have not been fully understood.3. Applications of graphene-based materials in nanomedicine
Graphene-based materials have extensively been exploited for
standard treatment options including surgical resection alongside
therapeutic strategies (such as chemotherapy, radiotherapy and
photodynamic therapy). The first study on graphene in drug de-
livery was reported by the Hongjie Dai group in 2008 [24]
demonstrating that doxorubicin, a widely used cancer drug can be
loaded to nano-graphene oxide functionalized with antibody for
selective targeting of tumors in vitro. Since then, many significant
studies on graphene-based materials for biosensors, drug delivery
systems and bio-imaging have further been reported [25,26]. The
sustained release and capacity of graphene can potentially be
triggered to granules/cell membrane interaction for improved
release and delivery of therapeutic drugs to be expressed first at cell
membrane and become subsequently internalized in a cell. Some
evidences of such capacity for graphene oxide and GQDs have also
been reported [27,28], but the mechanistic explanation of the
generation of reactive oxygen and nitrogen species by graphene-
based materials is still lacking in a way to empirically inform
their multifunctional role in disease management. Another pho-
tomedicinal process of great importance is the significant influence
of the stimulus of light on graphene nanostructures (such as GQDs),
which directly effects the production of reactive oxygen species
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graphene from its photo- and dark toxicity exposures within the
target and non-target tissues [29]. These radical molecules can be
used to closely mimic therapeutic functions and thereby open up
new pathways to anticancer nanomedicine [23,30,31]. Graphene-
based materials produce ROS through surface chemical reactions,
defects, and impurities [32]. There is a variety of functional groups
present in chemically-modified nanostructured graphene which
may motivate ROS generation [32]. The role of redox signaling has
not yet been explored for the delivery of drugs, although chemical
preparation of graphene involves exfoliation using sodium nitrate
which can in turn release reactive nitrogen species in the cells. For
example, the chemical exfoliation of graphene oxide is commonly
carried out by using graphite flakes in H2SO4 and NaNO3 to oxidize
graphite flakes into graphite oxide [33]. The chemical reaction for
this step is: 2 NaNO3 þ H2SO4¼ 2 HNO3 þ Na2SO4. Oxidation by
HNO3 may liberate gaseous NO2 and/or N2O4. The addition of
NaNO3 increases the interlayer distance marginally with improved
basal planes oxidation of graphite. As a result, graphite flakes are
broken into smallest sheets (single or few layers) with maximum
functionalization on the basal planes. After the exfoliation of gra-
phene oxide, hydrazine is the commonly used reducing agent to
reduce the functional groups and also to enhance surface area and
porosity [34e36]. As a result of using hydrazine, nitrogen tends to
remain covalently bonded to the surface of graphene in the form of
hydrazones, amines, aziridines and/or other analogous species. On
this basis, it is important to quantify and analyse nitrogen-centred
radicals present in graphene nanostructures. The commonly used
chemical methods to prepare graphene rely on the usage of toxic
solvents and reducing agents. Elevated levels of reactive oxygen
and nitrogen species are involved in the hyperactivation of cellular
oxidases and mitochondrial dysfunction as a result of cell damage
by inducing or repressing nitrosative stresses [37]. In addition to
this key role, reactive nitrogen species have been implicated as a
regulatory mediator in signaling pathways of many living cells,
including cardiovascular cells, neural cells, vascular muscle cells
and platelets [38]. They may alter mitochondrial proteins thiols in
posttranslational modification arena as a result of combined effect
of their interactions with ROS [23]. Graphene-based materials that
are responsive to generate reactive oxygen and nitrogen species
need to be strategically used as therapeutic and/or diagnostic
agents for their specific and selective disease targets.
The graphene nanostructures designed and reported so far in
the literature reveal remarkable efficacy for their in vitro and in vivo
applicability against several malignant tumors and cell lines
[1,5,17,39]. Nevertheless, the chemistry of the controlled, selective,
and sustained release and yield of reactive oxygen, and in particular
nitrogen, species needs to be adjusted to better achieve their bio
functionality. For example; reactive oxygen and nitrogen species
released from graphene, in the combination of photodynamic
therapy and chemotherapy along with bio-imaging technique, can
further enhance the effects of graphene in disease treatment.
Recently, Ge et al. [40] have reported GQDs as a photosensitizer
which can produce singlet oxygen with a quantum yield of ~1.3.
They have demonstrated these quantum dots as a selective imaging
and efficient therapy agent using in vitro and in vivo models.
Importantly, tumors tend to survive under hypoxic conditions,
which are characteristic features of tumors metastasis and drug
resistance. Such low oxygen environments have not been taken
into account while using graphene as anti-cancer therapeutic
agent. Design of hypoxia activated modulators and reductants with
graphene-based materials could help improve the anticancer effi-
cacy of such nanomaterials-based therapies to target/leverage tu-
mor hypoxia. Reoxygenation therapeutic strategies could also be
utilized to produce oxygen filled nanomedicines in addition toconventional therapies (chemotherapy, radiotherapy, photo-
thermal and photodynamic therapies). It is well known that
photodynamic therapy is particularly efficient in the treatment of
superficial tumors, but has limitations due to low yields of ROS and
unwanted side effects. Considerable attention needs to be paid
towards the improved production of redox mediated species by
graphene-based materials for their selective and targeted delivery
in specific cell types to potentially deal with redox signaling
pathways for the point-of-care management and treatment of
many diseases including acute and chronic wound infections,
cancer, and neurological disorders. For example, porous graphene
could potentially be prepared to store and release therapeutic
levels of nitric oxide for controlling wound biofilms infections.
Moreover, the antibacterial actions of graphene have been utilized
as surface coatings, colloidal dispersions and photodynamic ther-
apy agents [41,42]. Antibacterial activities of graphene revealed that
it can possibly be used as antimicrobial products such as wound
dressings and infection-protective coatings [43e45]. These anti-
bacterial features of graphene can be ascribed to their direct
interaction with bacteria, causing destruction of their membrane
which subsequently leads to RNA leakage, release of intracellular
components and lipid peroxidation [44,45]. These antimicrobial
capabilities of graphene can be extended to exploit their antiviral,
antifungal and anti-inflammatory actions in combination with
storage and sustained release of nitric oxide within graphene
structures. This feature letter emphasises the key challenges posed
in nanomedicine when dealing with clinical translation of this
‘miracle’ material as tiny robots which can bemasked by the impact
of biological outcomes of different forms of graphene.
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